DAFNA Capital Management LLC Has $1.21 Million Stock Holdings in Palvella Therapeutics, Inc. $PVLA

Key Points

• DAFNA Capital Management LLC reduced its stake in Palvella Therapeutics by 39.3%, owning 43,348 shares after selling 28,104 shares during the first quarter.
• Palvella Therapeutics reported a quarterly EPS of (0.86), missing the consensus estimate of (0.78), and is projected to post a -3.69 EPS for the current year.
• Several analysts set new price targets for Palvella Therapeutics, with Canaccord Genuity now targeting $66.00 and HC Wainwright at $75.00, reflecting confidence in the stock's potential growth.

DAFNA Capital Management LLC reduced its stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 39.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,348 shares of the company's stock after selling 28,104 shares during the quarter. DAFNA Capital Management LLC owned 0.39% of Palvella Therapeutics worth $1,213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PVLA. Suvretta Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at $8,574,000. BVF Inc. IL acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at $8,359,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at $7,847,000. Adams Street Partners LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at $4,916,000. Finally, Royce & Associates LP acquired a new stake in shares of Palvella Therapeutics in the first quarter valued at $2,002,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PVLA. Lifesci Capital began coverage on Palvella Therapeutics in a research note on Monday, August 4th. They issued an "outperform" rating and a $90.00 target price for the company. Canaccord Genuity Group raised their target price on Palvella Therapeutics from $52.00 to $66.00 and gave the company a "buy" rating in a research note on Tuesday, August 19th. Truist Financial began coverage on Palvella Therapeutics in a research note on Monday, July 21st. They issued a "buy" rating and a $56.00 target price for the company. Chardan Capital raised their price target on Palvella Therapeutics from $50.00 to $60.00 and gave the company a "buy" rating in a report on Friday, August 15th. Finally, HC Wainwright raised their price target on Palvella Therapeutics from $38.00 to $75.00 and gave the company a "buy" rating in a report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $58.50.

Palvella Therapeutics Trading Up 1.5%

Shares of NASDAQ:PVLA traded up $0.80 during trading on Wednesday, hitting $53.51. 50,512 shares of the company's stock traded hands, compared to its average volume of 97,680. Palvella Therapeutics, Inc. has a 52 week low of $11.17 and a 52 week high of $57.19. The company has a market cap of $591.82 million, a price-to-earnings ratio of -4.42 and a beta of -0.03. The company has a 50-day moving average price of $37.39 and a 200-day moving average price of $28.46.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.08). On average, analysts predict that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.